Comparing 3 versus 7 days systemic administration of Amoxicillin (AMX) and Metronidazole (MET) in severe chronic periodontitis patients
Not Applicable
Completed
- Conditions
- Severe chronic periodontitisOral Health
- Registration Number
- ISRCTN17605083
- Lead Sponsor
- Department of prosthodontics, University of Medicine and Pharmacy Iuliu Hatieganu
- Brief Summary
2016 Results article in https://pubmed.ncbi.nlm.nih.gov/27027501/ (added 26/11/2021) 2017 Results article in https://pubmed.ncbi.nlm.nih.gov/28662049/ (added 10/07/2023) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/33004857/ (added 10/07/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 102
Inclusion Criteria
1. >30 years
2. Diagnosis of severe chronic periodontitis (Armitage 1999)
3. = 12 natural teeth
4. = 1 site/quadrant with pocket depth = 6mm
5. Full-mouth plaque scores = 25% (O`Leary 1972)
6. systemically healthy
7. No allergies for penicillin or 5-nitroimidazole derivates
Exclusion Criteria
1. Non-surgical periodontal therapy within 12 months
2. Systemic/local antibiotics within the previous 3 months
3. Medication that could interact with amoxicilline or metronidazole
4. Pregnancy/lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of the number of sites per patient with pocket depth = 6 mm between baseline and 6 months
- Secondary Outcome Measures
Name Time Method Secondary variables were changes in: probing pocket depth, clinical attachment level, bleeding on probing, furcation involvement, full-mouth plaque score -FMPS-, gingival bleeding index -GBI, number of sites per patient with PD = 6 mm, number of sites per patient = 5 mm, bacterial load of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tanerella Forsythia, Treponema denticola, Prevotella intermedia, levels of IL-10. IL-1ß, TNF-alpha, MMP-8.